Anti-NMDA receptor antibodies and methods of use
US12221484B2 · kind B2 · utility
Assignee
Inventors
Key dates
| Filing date | Jun 8, 2019 |
| Grant date | Feb 11, 2025 |
| Priority date | — |
| Expiry date | Aug 6, 2041 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/28
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
A recombinant, synthetic or monoclonal human antibody or fragment thereof that binds to an N-methyl-D-aspartate Receptor (NMDAR) epitope, which antibody or fragment comprises at least one a heavy chain variable domain sequence encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NOs. 1, 3, or 5; or at least one a light chain variable domain sequence encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NOs: 2, 4, or 6. Assays for diagnosis of ANRE employ these NMDAR-binding antibodies, constructs, or epitope binding fragments. In one embodiment, multiple of the NMDAR-binding antibodies or fragments are used as controls because they bind non-overlapping target sequences on the NMDAR ATD.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.